Cancer Types   /   Breast Cancer   /   Treatment Options   /   Hormonal Therapy

Hormonal Therapy

Hormonal

Does hormone replacement therapy increase the risk of breast cancer
I have a very simple question. Does hormone replacement therapy increase the risk of breast cancer? Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds: Hormone-replacement therapy (HRT) has been an issue for women's health since its introduction in the mid-1970s. HRT's proposed benefits included menopause symptom

The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort.
Presenter: S.K.L.ChiaPresenter's Affiliation: British Columbia Cancer AgencyType of Session: ScientificBackground Metastatic Breast Cancer is an extremely prevalent diagnosis. Median OS for these patients has historically been 12-24 months. No studies have shown population based data indicating improved survival with newer chemotherapeutic agents

A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are

Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?
Presenter: S. Domchek Presenter’s Institution: U. of Pennsylvania School of Medicine Background Research has shown that women who carry the BRCA mutations benefit from risk-reduction procedures to reduce their risk of developing breast and ovarian cancers. The best risk-reduction strategy appears to be surgical removal of the

Soy and Breast Cancer: Should breast cancer survivors eat soy foods?
What are soy foods? Examples of soy foods include: soybeans (also called edamame), soybean sprouts, tofu, soymilk and fermented soybeans (also called tempeh). These traditional soy foods have been used in many cultures as good sources of protein for thousands of years. More recently, processed soy protein has been added to a variety of foods,

---

Cytoreduction

RTOG Protocol 92-02: A phase II trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
Presenter: Gerald E. Hanks Affiliation: RTOG Background: Controversy exists on the integration of hormonal therapy for the treatment of locally advanced prostate cancer. This trial was designed to determine if long term androgen ablation is superior to short term ablation. Materials and Methods: 1554 patients with

Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949
Presenter: Robert Charles Flanigan Affiliation: Southwest Oncology Group Background: Metastatic renal cancer has a poor prognisis and is classically highly resistant to chemotherapy. A number of case series have reported a benefit to neprhectomy in patients with metastatic renal cancer. This prospective randomized trial was

A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate.
Presenter: Gerald E. Hanks Affiliation: Fox Chase Cancer Center Background: Radiation therapy is a long-standing treatment option for prostate cancer Previous studies by the RTOG and the EORTC have demonstrated improved disease-specific survival using the combination of adjuvant hormone therapy and radiation therapy The duration of

---

Hormone

Does hormone replacement therapy increase the risk of breast cancer
I have a very simple question. Does hormone replacement therapy increase the risk of breast cancer? Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds: Hormone-replacement therapy (HRT) has been an issue for women's health since its introduction in the mid-1970s. HRT's proposed benefits included menopause symptom

The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort.
Presenter: S.K.L.ChiaPresenter's Affiliation: British Columbia Cancer AgencyType of Session: ScientificBackground Metastatic Breast Cancer is an extremely prevalent diagnosis. Median OS for these patients has historically been 12-24 months. No studies have shown population based data indicating improved survival with newer chemotherapeutic agents

A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are

Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?
Presenter: S. Domchek Presenter’s Institution: U. of Pennsylvania School of Medicine Background Research has shown that women who carry the BRCA mutations benefit from risk-reduction procedures to reduce their risk of developing breast and ovarian cancers. The best risk-reduction strategy appears to be surgical removal of the

Soy and Breast Cancer: Should breast cancer survivors eat soy foods?
What are soy foods? Examples of soy foods include: soybeans (also called edamame), soybean sprouts, tofu, soymilk and fermented soybeans (also called tempeh). These traditional soy foods have been used in many cultures as good sources of protein for thousands of years. More recently, processed soy protein has been added to a variety of foods,

---

Ablation

Radioactive iodine (I-131) Therapy for Thyroid Cancer
Radioactive iodine (RAI) is a therapy used in the treatment of some thyroid cancers, specifically papillary and follicular thyroid cancer. For the thyroid gland to make thyroid hormone, the first step in the process is for the thyroid cells to "take up" iodide from the bloodstream. Iodide is one of the building blocks used to produce

Interventional Radiology: The Basics
What is Interventional Radiology? Interventional Radiology (IR) is one of the most technologically advanced and fastest growing specialties of modern medicine. As a subspecialty of radiology, IR utilizes image-guidance via ultrasound, x-ray, CT, MRI, and fluoroscopy to perform advanced minimally-invasive procedures in an operating room type

Radiofrequency Ablation
What is Radiofrequency Ablation? Radiofrequency ablation (RFA) is a treatment for tumors found in the liver, lung and kidney and is being studied in breast and bone tumors. In some cases, tumors cannot be destroyed by chemotherapy, radiation or surgery. RFA uses heat to attack these tumors, destroying them without hospitalization and with few side

Prostate cancer in African-American men: Outcome following radiation therapy with or without adjuvant androgen ablation
Reviewers: Kenneth Blank, MD Source: International Journal of Radiation Oncology, Biology, and Physics, October 1, 1998, Vol 43 No. 2 p 517Prostate cancer is the most common cancer in American males and the second leading cause of cancer death behind lung cancer. When caught early, prostate cancer is often cured with radiation, surgery or

Testosterone Recovery Following Prolonged Adjuvant Androgen Ablation for Prostate Carcinoma
Authors: T Pickles, A Agranovich, E Berthelet, et al. Source: Cancer 2002; 94: 362-7 Background The use of androgen ablation (AA) has become more common in the treatment of prostate cancer. Androgen ablation has a proven survival benefit in patients with advanced (T3-4, or lymph node positive) disease and in those with high Gleason Score

---

Hormone-Suppressing

Male Bone Density Decreases at a Steady Rate During Hormone-Suppressing Prostate Cancer Treatment
The same bone loss seen in women who aren't producing estrogen is now being seen soon after men suppress testosterone and androgen production during prostate cancer therapy. These male hormones are known to stimulate the early growth of prostate cancer, so at the first signs of a rising PSA level -- a test that measures a protein produced by

Acupuncture for the Treatment of Vasomotor Symptoms in Breast Cancer Patients Receiving Hormone Suppression Treatment
Presenter: E. M. Walker, MDPresenter's Affiliation: Henry Ford Health System Department of Radiation Oncology, Detroit, MIType of Session: ScientificBackground Anti-estrogen hormonal therapy given as treatment for breast cancer can induce early menopause, and often causes patients to experience debilitating vasomotor symptoms, mainly hot

---

Tamoxifen

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial
Authors: Joan Houghton, et al. Affiliation: UKCCCR DCIS Working Party / DCIS trialists in the UK, Australia, and New Zealand Source: Lancet. 2003 Jul 12;362(9378):95-102 Introduction The establishment of breast screening programs in the UK, Australia, and New Zealand resulted in an increase in the diagnosis of ductal carcinoma in situ

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
Reviewers: John Han-Chih Chang, MD Source: Lancet 1999 Jun 12; Volume 353: pages 1993 - 2000BackgroundWe have shown previously that lumpectomy with radiation therapy was more effective than lumpectomy alone for the treatment of ductal carcinoma in situ (DCIS). We did a double-blind randomized controlled trial to find out whether lumpectomy,

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
Reviewers: John Han-Chih Chang, MD Source: Lancet 1999 May 15; Volume 353(Number 9165): 1641-8Background/Discussion/CritiqueThe New England Journal publications in 1997 from Denmark and Canada demonstrated a survival benefit for postmastectomy radiation therapy (RT) in premenopausal women with high risk breast cancer. The benefits of tamoxifen in

Tamoxifen for weakly positive Estrogen and Progesterone breast cancers
Dear OncoLink "Ask The Experts," I am a 31-year old ER negative and "weakly" PR positive breast cancer patient. I have had a mastectomy with no lymph node involvement and chemotherapy and now deciding whether to go on Tamoxifen. Does your practice recommend Tamoxifen for "weakly" PR positive patients?Julia Draznin Maltzman, MD,

The impact of concurrent versus sequential tamoxifen and radiation therapy in breast cancer patients undergoing breast conservation therapy.
Presenter: Vasathi J. ChristnesenPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Hormonal Therapy plays an important role in the adjuvant therapy of breast cancer patients. The optimal sequencing of tamoxifen therapy and radiation (XRT) is not well established. This study was conducted in order

---

Femara

Letrozole (Femara®)
Pronounced: LET-roe-zole Classification: Aromatase Inhibitor About Letrozole Letrozole is an aromatase inhibitor that works to decrease the overall levels of estrogen in a woman's body. In women who have gone through menopause, estrogen is mainly produced by converting androgens (sex hormones produced by the adrenal glands) into estrogens. An

Average response to Femara
Dear OncoLink "Ask The Experts," How long does the drug "Femara" last? What is the next drug of choice after that? I was on Tamoxifen for 18 months and I have been on Femara for 15 months with very good results. Kevin R. Fox, MD, Assistant Director, Clinical Affairs and Associate Professor of Hematology/Oncology at the Abramson Cancer Center

---

Estrogen Receptor

Tamoxifen for weakly positive Estrogen and Progesterone breast cancers
Dear OncoLink "Ask The Experts," I am a 31-year old ER negative and "weakly" PR positive breast cancer patient. I have had a mastectomy with no lymph node involvement and chemotherapy and now deciding whether to go on Tamoxifen. Does your practice recommend Tamoxifen for "weakly" PR positive patients?Julia Draznin Maltzman, MD,

Estrogen plus progestin (E+P) and breast cancer incidence and mortality
Presenter: Rowan T. Chlebowski Presenter's Affiliation: Women's Health Initiative, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA Background The Women's Health Initiative (WHI) was a major research program launched in 1991 to address the most common causes of death, disability and poor quality of

Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101)
Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive breast cancer are a topic of much research. The benefit of chemotherapy in node-positive breast

BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer.
Presenter: B.J. ThurlimannPresenter's Affiliation: BIG 1-98 Collaborative, Bern, SwitzerlandType of Session: ScientificBackground Letrozole is a drug in a class of medications known as aromatase inhibitors, which almost completely inhibit the synthesis of estrogen. Tamoxifen is an estrogen receptor blocker.

A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are

---

Progesterone Receptor

Tamoxifen for weakly positive Estrogen and Progesterone breast cancers
Dear OncoLink "Ask The Experts," I am a 31-year old ER negative and "weakly" PR positive breast cancer patient. I have had a mastectomy with no lymph node involvement and chemotherapy and now deciding whether to go on Tamoxifen. Does your practice recommend Tamoxifen for "weakly" PR positive patients?Julia Draznin Maltzman, MD,

Estrogen receptor negative breast cancers
Dear OncoLink "Ask The Experts," Does breast cancer run along some continuum from estrogen-receptor positive to estrogen-receptor negative tumors? Are ER+ tumors a different disease than ER- tumors? I have been diagnosed with an ER- breast cancer and I am confused as to whether I am at increased risk of recurrence and general guidelines for

Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101)
Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive breast cancer are a topic of much research. The benefit of chemotherapy in node-positive breast

BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer.
Presenter: B.J. ThurlimannPresenter's Affiliation: BIG 1-98 Collaborative, Bern, SwitzerlandType of Session: ScientificBackground Letrozole is a drug in a class of medications known as aromatase inhibitors, which almost completely inhibit the synthesis of estrogen. Tamoxifen is an estrogen receptor blocker.

A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are